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Abstract
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BACKGROUND: Compared with adults, phenotypic characterization of children with asthma is
still limited and it remains difficult to predict which children with asthma are at highest risk for
poor outcomes.
OBJECTIVE: To identify latent classes in a large population of treatment-adherent children with
mild to moderate asthma enrolled in clinical trials and determine whether latent class assignment
predicts future lung function abnormalities and exacerbation rate.
METHODS: Latent class analysis was performed on 2593 children with mild to moderate asthma
aged 5 18 years, with 19 variables encompassing demographic characteristics, medical history,
symptoms, lung function, allergic sensitization, and type 2 inflammation. Outcomes included lung
function and the annualized exacerbation rate at 12 months of follow-up.

Author Manuscript

RESULTS: Five latent classes were identified with differing demographic features, asthma
control, sensitization, type 2 inflammatory markers, and lung function. Exacerbation rates were
1.30 ± 0.12 for class 1 (multiple sensitization with partially reversible airflow limitation), 0.90 ±
0.05 for class 2 (multiple sensitization with reversible airflow limitation), 0.87 ± 0.08 for class 3
(lesser sensitization with reversible airflow limitation), 0.87 ± 0.05 for class 4 (multiple
sensitization with normal lung function), and 0.71 ± 0.06 for class 5 (lesser sensitization with
normal lung function). Lung function abnormalities persisted in class 1 at 12 months.
CONCLUSIONS: Children with mild to moderate asthma are a heterogeneous group. Allergic
sensitization and lung function may be particularly useful in identifying children at the greatest
risk for future exacerbation. Additional studies are needed to determine whether latent classes
correspond to meaningful phenotypes for the purpose of personalized treatment.
Keywords
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Asthma in children; Phenotype; Asthma exacerbation; Asthma control; Asthma outcomes; Latent
class analysis; Lung function; Type 2 inflammation; Aeroallergen sensitization

INTRODUCTION
Asthma currently affects 8.4% of all children in the United States.1 Yet despite widespread
availability of inhaled corticosteroids (ICSs) and standardization of asthma treatment
guidelines, asthma control remains suboptimal in most children.2,3 Consequently, more than
J Allergy Clin Immunol Pract. Author manuscript; available in PMC 2021 September 01.
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50% of all children with asthma experience at least 1 exacerbation each year,1 including
children with nonsevere asthma who have less troublesome day-to-day symptoms4 and
normal lung function.5 The morbidity from exacerbations of asthma in children is significant
and contributes to missed school/work days,6–8 impaired caregiver functional status,9 and a
growing personal10 and societal11 economic burden estimated at more than $80 billion
annually.12

Author Manuscript

Although the factors responsible for poor asthma control and asthma exacerbations in
children are complex,13 there is also growing recognition that children with asthma are a
heterogeneous group, with many underlying biological pathways or “endotypes” that
contribute to differing phenotypic disease presentations, differential responses to asthma
treatments, and varied clinical outcomes.14–21 Mandates for “personalized” versus “one size
fits all” treatment of children with asthma have therefore been issued,22 but several
challenges persist. First, compared with adults, phenotypes of childhood asthma are
understudied and still unclear. There are also notable differences in the clinical
manifestations of asthma between adults and children such as the magnitude of lung
function deficits23 and exacerbation frequency24 that prohibit extrapolation of phenotypic
findings between age groups. Second, most previous phenotypic analyses in children have
focused on difficult-to-treat or severe asthma populations,25 which are not the predominant
group encountered in most clinical practice settings. Therefore, phenotypic characterization
of children with asthma is still limited and it remains difficult to predict which children with
asthma are at the highest risk for poor outcomes (such as recurrent exacerbations) across the
spectrum of disease severity.
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Given these knowledge gaps, we applied latent class analysis (LCA) to a cohort of more
than 2500 well-characterized children with mild to moderate persistent asthma aged 5 to 18
years with documented adherence to asthma controller therapies enrolled in previous
National Heart, Lung and Blood Institute asthma network phase 3 clinical trials. The
purpose was to (1) identify latent classes and (2) determine whether latent class assignment
predicts subsequent lung function abnormalities and exacerbation rate at 12 months of
follow-up. We hypothesized that a latent class distinguished by underlying type 2
eosinophilic inflammation and airflow limitation despite nonsevere disease would be
identified and would have the lowest lung function and highest exacerbation rate by 1 year
of follow-up.

METHODS
Author Manuscript

LCA was performed on 8 National Heart, Lung and Blood Institute clinical trials involving
2593 children with mild to moderate asthma aged 5 to 18 years: the Childhood Asthma
Management Research Program (CAMP, NCT00000575),26,27 Characterizing the Response
to a Leukotriene Receptor Antagonist and an Inhaled Corticosteroid (no NCT),28–30
Pediatric Asthma Controller Trial (NCT00272506),31,32 Best Add-On Therapy Giving
Effective Response (NCT00395304),20,33 Treating Children to Prevent Exacerbations of
Asthma (NCT00394329),34 Step-Up Yellow Zone Inhaled Corticosteroids to Prevent
Exacerbations (NCT02066129),35 Best African American Response to Asthma Drugs
(NCT01967173),21 and Steroids in Eosinophil Negative Asthma (NCT02066298).36 Details
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of these studies are presented in Table E1 in this article’s Online Repository at www.jaciinpractice. org. All studies were overseen by dedicated quality control committees and data
coordinating centers and used similar intake questionnaires. Paper case report forms were
entered electronically and mailed to the data coordinating center for review and accuracy
upon completion. Each center maintained staff and site certification and used the same
manual of procedures for characterization. Written informed consent was obtained from all
caregivers, and written or verbal assent was obtained from all participants for trial
participation and secondary analyses. CAMP data were obtained from BioLINCC through a
material transfer agreement (A.M.F.). Other study data were used with the permission of
network principal investigators (coauthors).
Participants
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All participants with persistent asthma with documented adherence to paper or electronic
diaries were included in this analysis (N = 2593). Thresholds for acceptable adherence were
defined as more than 75% to 80% of expected diaries completed during the study run-in
periods. In each study, asthma was physician-diagnosed and was confirmed by symptom
thresholds (ie, symptoms more than twice weekly off therapy or well controlled with daily
asthma therapy). Most of the studies also had 12% or more absolute reversibility in the
FEV1 after bronchodilator administration or airway hyper-reponsiveness to methacholine
(ie, provocative concentration causing a 20% decline in FEV1 [PC20] <12.5 or <16 mg/mL)
as criteria for study entry.
Participant characterization procedures

Author Manuscript
Author Manuscript

Participants completed questionnaires pertaining to demographic characteristics, family
history, child allergy and respiratory symptoms, and treatment of symptoms including
medications and health care utilization. A subset of participants (n = 1551 [59.8%]) also
completed the Asthma Control Test (ACT)37,38 and the 6-question Asthma Control
Questionnaire (ACQ).39 Peripheral blood eosinophils and total serum IgE were quantified in
clinical laboratories. Spirometry with bronchodilator reversibility was performed at baseline
and after receipt of 2 to 4 inhalations of albuterol sulfate (90 mg per actuation) delivered by
metered-dose inhaler. Spirometry was conducted according to published standards at the
time of the test.40 FEV1, forced vital capacity (FVC), and the ratio of FEV1/FVC were
recorded from the best of 3 attempts. Sensitization was assessed by skin testing or specific
IgE testing for the following aeroallergens common to each study: dust mite (mix),
cockroach (mix), cat dander, dog dander, mold (mix), grass (mix), tree (mix), and weed
(mix). Skin testing was performed using the Multi-test II (Lincoln Diagnostics, Decatur, Ill)
prick technique. Test results were considered positive if the prick resulted in a wheal with a
mean diameter (mean of maximum and 90° midpoint diameters) that was at least 3 mm
greater than that produced by the saline control. Specific IgE levels were quantified at
centralized laboratories. Tests with levels more than 0.34 IU/mL were considered positive.
Exhaled nitric oxide was also measured by online methods in a subset of participants.41
Variable selection and handling
Variable selection is detailed in the Online Repository and in Table E2 in this article’s
Online Repository at www.jaci-inpractice. org. Dichotomous variables included (1) age
J Allergy Clin Immunol Pract. Author manuscript; available in PMC 2021 September 01.
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group (6–11 vs >11 years), (2) sex, (3) hospitalization in the past year, (4) intensive care unit
admission for asthma (ever), (5) blood eosinophil group (<4% or ≥4%), (6) sibling with
asthma, (7) parent with asthma, (8) sensitization to pets, (9) sensitization to other
aeroallergens, (10) indoor pet, and (11) tobacco smoke exposure. Categorical variables
included (1) race (white/Caucasian, black/African American, and other/mixed), (2) number
of unscheduled visits for asthma in the past year (0, 1, ≥ ≥2), (3) prebronchodilator FEV1 z
score (< −1.64, −1.64 to 0, >0), (4) prebronchodilator FEV1/FVC z score (< −1.64, −1.64 to
0, >0), (5) postbronchodilator FEV1 z score (< −1.64, −1.64 to 0, >0), (6) IgE level in kU/L
(<100, 100–500, 500–1000, >1000), (7) body mass index (BMI) percentile (<60%, 60%
−90%, >90%), and (8) asthma control quartile (lowest = worst control; highest = control)
obtained from either the ACT or the best ACQ score. Lung function data were expressed as
z scores and interpreted according to lower limit of normal (LLN) values established by the
Global Lung Function Initiative prediction equations.42
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Outcomes
Outcomes included lung function (pre- and postbronchodilator FEV1, FVC, FEV1/FVC) and
the annualized rate of exacerbation at the end of follow-up. For the CAMP study, outcomes
were assessed over the first year only. The definition of exacerbation used was proposed by a
National Institutes of Health Working Group43 and was defined as escalation of symptoms
resulting in treatment with systemic corticosteroids (ie, dexamethasone, prednisone, or
prednisolone equivalent to 2 mg/kg/d for 2 days followed by 1 mg/kg/d for 2 days). Two
courses of systemic corticosteroids had to be separated by at least 1 week to count as 2
exacerbations.
Latent class analyses
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LCA was performed with SAS software version 9.4 (SAS Institute, Cary, NC) using the
PROC LCA procedure44 and a maximum likelihood model algorithm that allows missing
data under the missing completely at random assumption, which was tested and evaluated.
Models of 1 to 8 latent classes were repeatedly fitted with the number of latent classes in a
stepwise fashion. Models were freely estimated with no specified parameter restrictions.
Conditional probabilities (probability of selected characteristics within a class) and posterior
probabilities (probability of latent class membership for each participant) were calculated.
Best fit was assessed by comparison of the bootstrapped P values for the likelihood ratio test
and the Bayesian information criterion test. Each participant was assigned to the latent class
with the highest membership probability.
Outcome analyses
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End of follow-up lung function and the annualized rate of exacerbations were assessed in
each latent class irrespective of treatment assignment with generalized linear models with
adjustment for study. Exploratory analyses were performed on parallel-arm treatment studies
(CAMP, Pediatric Asthma Controller Trial, Treating Children to Prevent Exacerbations of
Asthma, and Step-Up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations) with
asthma treatment assignment as follows: (1) placebo, (2) other asthma medication
(leukotriene receptor antagonist), nedocromil, or rescue ICS), or (3) daily ICS. Analyses
used a significance level of .05 without adjustment for multiple testing.
J Allergy Clin Immunol Pract. Author manuscript; available in PMC 2021 September 01.
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RESULTS
A total of 2593 children were included in the LCA. Evaluations were done for 4-, 5-, and 6class solutions; the 5-class solution was chosen as best fit and yielded a high class
membership probability for all participants with acceptable fit statistics (adjusted Bayesian
information criterion: 26,930.16; entropy: 0.88). The distribution of study variables by latent
class assignment is presented in Table I. By design, each LCA variable was significantly
different between latent classes. The distribution of studies within each latent class is shown
in Figure 1. Other features of the study participants are presented in Table II. To simplify the
discussion, latent classes were assigned a summary label. Key features of the 5 latent classes
are detailed herein.
Latent class 1: Multiple sensitization with partially reversible airflow limitation

Author Manuscript
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Latent class 1, titled “multiple sensitization with partially reversible airflow limitation,”
included 244 children (9.4%). Children in this latent class were predominantly white/
Caucasian males and had the poorest overall asthma control. This class also had the highest
proportion of Hispanics. In addition, this class was characterized by multiple sensitization to
pets and other aeroallergens, the highest blood eosinophils, and high total serum IgE
concentrations, with 36% of children having concentrations more than 1000 kU/L. Forty-one
percent of children in this latent class were not receiving controller therapy at study
enrollment and 11.5% had been hospitalized for asthma in the previous year. Lung function
values were also the lowest in this group, and 100% of children in this class had
prebronchodilator FEV1 z scores below the LLN (ie, < −1.64), respectively. Lung function
values remained the lowest in this latent class after bronchodilation and 16% of children had
postbronchodilator FEV1 z scores below the LLN. Airway hyperresponsiveness to
methacholine was also the greatest in this latent class.
Latent class 2: Multiple sensitization with reversible airflow limitation
This was the largest latent class, with 926 children (35.7%), and was titled “multiple
sensitization with reversible airflow limitation.” Children in this latent class were similar to
those in latent class 1 with regard to demographic characteristics, sensitization patterns, and
markers of type 2 inflammation, but had fewer historical severe exacerbations requiring
hospitalization and lesser exposure to tobacco smoke. All children in this latent class had
baseline FEV1 z scores above the LLN (ie, > −1.64). Lung function values improved further
with albuterol in nearly all children and only 0.8% of children had postbronchodilator FEV1
z scores below the LLN.

Author Manuscript

Latent class 3: Lesser sensitization with reversible airflow limitation
Latent class 3 included 315 children (12.1%) and was titled “lesser sensitization with
reversible airflow limitation.” This latent class included more females and more obese
children with fewer historical severe exacerbations requiring hospitalization than classes 1
and 2. Tobacco smoke exposure was also the greatest in this latent class, and most of the
children had either no sensitization (66%) or monosensitization (22%). Blood eosinophil
percentages and total serum IgE concentrations were also low in this group compared with
those in classes 1 and 2. Approximately 13% of children in this class had prebronchodilator
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FEV1 z scores below the LLN, respectively. Lung function values improved significantly
with albuterol in most of the children and only 4.2% of children had postbronchodilator
FEV1 z scores below the LLN.
Latent class 4: Multiple sensitization with normal lung function
Latent class 4 included 718 children (27.6%) and was titled “multiple sensitization with
normal lung function.” This class was similar to classes 1 and 2 but included more nonwhite/
non-Caucasian children with higher BMI percentiles. Like classes 1 and 2, this class was
characterized by multiple sensitization, elevated blood eosinophils, and elevated IgE, but had
a higher proportion of children (71.2%) who were treated with asthma controller
medications. Lung function values were also higher in this class compared with those in
classes 1 and 2, and 100% of children had baseline FEV1 z scores above the LLN.
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Latent class 5: Lesser sensitization with normal lung function
Latent class 5 included 390 children (15.0%) and was titled “lesser sensitization with normal
lung function.” This latent class was younger and included the highest proportion of females
and obese children with BMI percentiles of 95% or higher. Asthma control was also the
greatest in this group, although 18.6% of children still had asthma control values in the
lowest (ie, poorest) quartile. Sensitization patterns were similar to those in latent class 3,
with most of the children having either no sensitization (63%) or monosensitization (18%) to
allergens. Blood eosinophils and total serum IgE concentrations were also low and were
similar to concentrations observed in latent class 3. However, lung function was higher than
in class 3, and FEV1 z scores were above the LLN in 100% of children in this class. Airway
hyperresponsiveness to methacholine was still noted in this class, but methacholine PC20
values were higher than in the other classes.
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Sensitivity analyses
Given that the asthma control variable had a relatively large amount of missing data,
sensitivity analyses were performed excluding this variable from the LCA. As presented in
Table E3 in this article’s Online Repository at www.jaci-inpractice.org, exclusion of the
asthma control variable did not significantly change the results.
Outcome analyses
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Days to end of follow-up were 316 ± 95 for all participants (class 1, 328 ± 97; class 2, 322 ±
91; class 3, 308 ± 104; class 4, 316 ± 91; class 5, 302 ± 103). Pre- and postbronchodilator
lung function outcomes are presented in Table III. At the end of follow-up,
prebronchodilator lung function values improved in each latent class compared with study
entry, although children in latent class 1 still had the highest proportion of values below the
LLN. After bronchodilator administration, lung function values remained the lowest in class
1. In exploratory analyses, the change in FEV1 at the end of follow-up was not due to
asthma treatment (see Table E4 in this article’s Online Repository at www.jaciinpractice.org). Study treatment assignment also did not change the proportion of
participants with prebronchodilator FEV1 or FEV1/FVC z scores below the LLN in class 1
or 3 (Figure 2). However, children in class 2 had a greater lung function response with any
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asthma medication (ie, ICS or other asthma controller treatments such as leukotriene
receptor antagonist, nedocromil, or rescue ICS), whereas children in classes 4 and 5 had
greater lung function responses with ICSs (Figure 2).
Exacerbations occurred by the end of follow-up in 41.3% of participants (class 1, 52.5%;
class 2, 41.6%; class 3, 36.8%; class 4, 43.0%; class 5, 34.1%; P < .001). Latent class 1,
compared with the other classes, had more cumulative exacerbations and a significantly
higher annualized exacerbation rate (class 1, 1.30 ± 0.12; class 2, 0.90 ± 0.05; class 3, 0.87 ±
0.08; class 4,0.87 ± 0.05; class 5, 0.71 ± 0.07; P < .001) (Figure 3). In exploratory analyses,
ICS treatment significantly reduced exacerbation occurrence and the annualized
exacerbation rate by the end of follow-up in classes 1, 2, and 4 but not in classes 3 and 5
(Figure 4).
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DISCUSSION
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Although it is well recognized that children with asthma are a heterogeneous group,
personalized medicine for these children is not common practice. Instead, treatment
guidelines for children with asthma are still based on a “one size fits all” approach, with ICS
as the cornerstone of therapy, in part due to limited understanding of pediatric phenotypes
and their association with clinical outcomes. We therefore used LCA to uncover previously
unobservable patterns in a well-characterized, large study population of children with mild
to moderate persistent asthma enrolled in clinical trials. LCA has foundations in the social
sciences and is particularly useful for identifying class membership among participants with
multivariate categorical data. Although multivariable regression analyses could have been
used to identify factors associated with 1-year asthma outcomes in this population, the
present study sought to extend the existing body of hypothesis-directed literature through
consideration of multiple variables simultaneously. However, we recognize that this
approach is exploratory and hypothesis-generating; thus, the results should be interpreted in
the context of clinical and biological plausibility.

Author Manuscript

Using LCA, we identified 5 latent classes of children with mild to moderate asthma who
differed primarily in sensitization and lung function patterns. Consistent with our
hypothesis, we identified a latent class with markers of type 2 inflammation and persistent
airflow limitation (despite having mild to moderate disease) who also had the highest
exacerbation rate by 1 year of follow-up. However, exacerbations were noted in each of the
identified latent classes, albeit to a lesser extent. We therefore cannot conclude that our
latent classes reflect distinct phenotypes of mild to moderate asthma in children, but these
latent classes do provide some insight into potential (and differing) mechanisms of asthma in
children that could be probed in future analyses.
Our findings also have plausibility and are supported by the results of other studies. Previous
unsupervised analyses of children with severe asthma have also identified “clusters” with
more prominent type 2 inflammatory markers (ie, sensitization and eosinophils) and features
of greater asthma severity, including greater airflow limitation.45–48 Other independent
cluster analyses of children with nonsevere asthma or children across the severity spectrum
have noted similar results.49–53 However, few studies have attempted to validate the utility of
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the identified groupings with prospective outcomes. Although 1 study of predominantly
African American, inner-city children across the asthma severity spectrum identified a
cluster with prominent type 2 inflammation, multiple aeroallergen sensitization, significant
airflow limitation, and the highest proportion of exacerbations requiring treatment with
systemic corticosteroids, exacerbations were included as a variable in the clustering
algorithm and were not assessed independently of cluster assignment.52 Schatz et al46
attempted to validate their cluster assignments in children aged 6 to 11 years with difficultto-treat or severe asthma enrolled in the Natural History of Asthma: Outcomes and
Treatment Regimens study, but found no association with exacerbation occurrence, asthma
control, or quality of life at month 12. However, the clustering algorithm used in that study
included only 8 variables, which may have been inadequate to discriminate subtle
differences between groups. Furthermore, the percentage of children with exacerbations by
12 months was also relatively high in each cluster given the difficult-to-treat nature of the
patients and ranged from 37% to 53%.46 Most relevant to the present study, a previous
cluster analysis of the CAMP study (which excludes severe asthma) involving 18 variables
identified a highly atopic cluster of children with airflow limitation that also had the shortest
time to systemic corticosteroids for asthma exacerbation over 4 years of follow-up.50
However, in contrast to the present study, exacerbation rates and follow-up lung function
data were not reported in that analysis.43
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Although our observed associations between multiple sensitization, greater airflow
limitation, and exacerbations are not particularly novel, the magnitude of airflow limitation
and previous health care utilization observed in this population of children with mild to
moderate asthma is somewhat surprising. However, a recent review of asthma-related deaths
in the United Kingdom found that only 39% of asthma deaths occurred in patients with
severe asthma.54 Instead, 9% and 46% of deaths occurred in patients treated for mild and
moderate asthma, respectively, although that report also concluded that most of these
nonsevere patients likely had poorly controlled under-treated asthma as opposed to truly
mild or moderate disease.54 Although it is certainly possible that the inclusion criteria for
our included studies were insufficient in capturing mild to moderate asthma, it is also
recognized that, as a construct, asthma severity reflects the level of treatment required to
control symptoms and exacerbations at the present time55 and is not a static feature.56
Indeed, other analyses of children with mild to moderate asthma in the CAMP study noted
abnormal patterns of lung function growth in 75% of children, including markedly impaired
lung function growth in 11% of participants who subsequently met criteria for advanced
chronic obstructive pulmonary disease.23
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This study has several strengths, including the large sample size of diverse and
representative children across the United States. Because variable prescription of (and
adherence to) asthma controller medications such as ICS can complicate outcome
assessment, our focus on clinical trials with criteria for protocol adherence also increases the
likelihood that children were compliant with prescribed therapies. The close follow-up and
standardization of care in these clinical trials also helped to mitigate the impact of limited
access to primary care, which is an important determinant of asthma outcomes in general
populations.57 The clinical trials included in this analysis also assessed asthma exacerbations
in a standardized way and each used a consistent definition of exacerbation in accordance
J Allergy Clin Immunol Pract. Author manuscript; available in PMC 2021 September 01.
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with current recommendations for asthma outcomes research.43 This is also one of the few
studies intent on asthma phenotype discovery in children that attempted to validate outcomes
prospectively.
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Nonetheless, there are some limitations with our approach. First, we acknowledge that
model selection for LCA can be subjective. Although LCA models do allow for statistical
comparisons of model fit, the outputs (and patient groupings) are ultimately dependent on
the variables that are entered and the study population. Indeed, a study of different
unsupervised statistical learning methods found that different variable sets led to inconsistent
groupings of asthma that were not necessarily associated with severity.58 There are also no
criterion standard variables for the purpose of phenotype discovery. For example, one study
affirmed the importance of medication usage, current symptoms, lung function, parental
asthma, BMI, and age of asthma onset in the prediction asthma outcomes,58 whereas another
found that only 4 features identified by clinical experts (ie, age of onset, allergic
sensitization, severity, and recent exacerbations) were meaningful.49 Because many of the
variables used in our LCA model were assessed only at study entry, we were also unable to
assess the temporal stability of the identified latent classes and transition over time. The
relatively short, 1-year follow-up period and the inclusion of both school-age and adolescent
participants were also insufficient for examination of the role of puberty and sex hormones,
which have been shown to impact airway responsiveness and asthma prevalence on a
population level.59 The study interventions may have also impacted the outcome measures
selected for this analysis. For example, it is possible that the 12-month observations reflect
suboptimal treatment of certain subsets of participants. Furthermore, the CAMP cohort may
have impacted the findings because it represented most of the study population. There are
also potential limitations with the generalization of our findings. Although most of the
children in the present study were adherent, poor adherence to controller medications is
prevalent in general populations.13,60 Furthermore, economic hardships, limited access to
primary care,57 and ongoing exposures to environmental allergens and irritants61–63 are
known factors associated with poorer asthma outcomes in general populations of children
that may not have been well represented in this study.

CONCLUSIONS

Author Manuscript

Using LCA, we identified 5 latent classes of children with mild to moderate asthma that
differed with regard to multiple variables, most notably allergic sensitization and other
features of type 2 inflammation and lung function patterns. Although exacerbations were
noted in each latent class, exacerbation rates were the highest in children with multiple
sensitization and partially reversible airflow limitation, suggestive of more advanced disease.
These lung function deficits persisted at 1 year despite intervention with asthma controller
medications. Sensitization and lung function measures in children with mild to moderate
asthma may therefore be useful for predicting future risk in clinical settings. However,
additional studies are needed to determine whether our identified latent classes correspond to
meaningful phenotypes for the purpose of personalized treatment.
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What is already known about this topic?
In contrast to children with difficult-to-treat or severe asthma, phenotypic
characterization of children with mild to moderate persistent asthma is still limited and it
remains unclear which of these children are at the highest risk for poor outcomes.
What does this article add to our knowledge?
Five latent classes were identified. At 1 year, lung function deficits and exacerbations
were the greatest in the latent class with multiple sensitization and partially reversible
airflow limitation despite intervention with asthma controller therapy.
How does this study impact current management guidelines?
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Latent class analysis is useful for identifying risk factors in children with mild to
moderate asthma. Children with multiple sensitization and partially reversible airflow
limitation are a particularly vulnerable group that may warrant more aggressive
treatment.

Author Manuscript
Author Manuscript
J Allergy Clin Immunol Pract. Author manuscript; available in PMC 2021 September 01.

Fitzpatrick et al.

Page 16

Author Manuscript
Author Manuscript

FIGURE 1.

Distribution of studies within each latent class. BADGER, Best Add-On Therapy Giving
Effective Response; BARD, Best African American Response to Asthma Drugs; CAMP,
Childhood Asthma Management Research Program; CLIC, Characterizing the Response to a
Leukotriene Receptor Antagonist and an Inhaled Corticosteroid; PACT, Pediatric Asthma
Controller Trial; SIENA, Steroids in Eosinophil Negative Asthma; STICS, Step-Up Yellow
Zone Inhaled Corticosteroids to Prevent Exacerbations; TREXA, Treating Children to
Prevent Exacerbations of Asthma.
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FIGURE 2.
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Participants with (A) FEV1 and (B) FEV1/FVC below the LLN at the end of follow-up,
stratified by treatment assignment and latent class 1 (multiple sensitization with partially
reversible airflow limitation), 2 (multiple sensitization with reversible airflow limitation), 3
(lesser sensitization with reversible airflow limitation), 4 (multiple sensitization with normal
lung function), and 5 (lesser sensitization with normal lung function). *P <.05 vs placebo.
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FIGURE 3.
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(A) Exacerbation frequency and (B) annualized rate of exacerbations (mean ± SEM) at the
end of follow-up in latent classes 1 (multiple sensitization with partially reversible airflow
limitation), 2 (multiple sensitization with reversible airflow limitation), 3 (lesser
sensitization with reversible airflow limitation), 4 (multiple sensitization with normal lung
function), and 5 (lesser sensitization with normal lung function).
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FIGURE 4.
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(A) Exacerbation occurrence and (B) annualized exacerbation rate at the end of follow-up,
stratified by treatment assignment and latent class 1 (multiple sensitization with partially
reversible airflow limitation), 2 (multiple sensitization with reversible airflow limitation), 3
(lesser sensitization with reversible airflow limitation), 4 (multiple sensitization with normal
lung function), and 5 (lesser sensitization with normal lung function). *P < .05 vs placebo.
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2108 (81.3)
485 (18.7)

6–11 y

>11 y

1039 (40.1)

Female

244

8 (3.3)

692 (26.7)
264 (10.2)
74 (47, 92)

Other/mixed

BMI percentile

49 (20.1)

1080 (41.7)
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1678 (64.7)

479 (18.5)
952 (36.7)

1208 (46.6)

Indoor pet

Indoor dog

156 (6.0)

Intensive care unit admission for
asthma (ever)

Indoor cat

173 (6.7)

Hospitalization for asthma (ever)

74 (30.3)

60 (24.6)

109 (44.7)

21 (8.6)

28 (11.5)

161 (66.0)

422 (16.3)

≥2 visits (past year)

42 (17.2)

493 (19.0)

1 visit (past year)

41 (16.8)

85 (34.8)

0 visits (past year)

Unscheduled asthma visits

Sibling with asthma

134 (54.9)

763 (29.7)
1220 (47.0)

Parent with asthma

>90%

70 (28.7)

893 (34.7)

60%−90%

125 (51.2)

917 (35.6)

<60%

58 (34, 86)

72 (29.5)

1637 (63.1)

Black/African American

164 (67.2)

88 (36.1)

156 (63.9)

55 (22.5)

189 (77.5)

10.3 (8.0, 11.8)

White/Caucasian

Race

1554 (59.9)

Male

Sex

9.3 (7.4, 11.4)

2593

All participants

Age group

N

Feature

Class 1 (multiple
sensitization with
partially reversible
airflow limitation)

329 (25.5)

158 (17.1)

411 (44.4)

60 (6.5)

64 (6.9)

603 (65.1)

148 (16.0)

175 (18.9)

376 (40.6)

425 (45.9)

241 (26.4)

325 (35.6)

348 (38.1)

71 (44, 91)

88 (9.5)

238 (25.7)

600 (64.8)

339 (36.6)

587 (63.4)

218 (23.5)

708 (76.5)

9.9 (8.0, 11.9)
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sensitization with
reversible airflow
limitation)

120 (38.1)

71 (22.5)

163 (51.7)

14 (4.4)

7 (2.2)

206 (65.4)

37 (11.7)

72 (22.9)

155 (49.2)

134 (42.5)

110 (34.9)

95 (30.2)

110 (34.9)

76 (46, 94)

22 (7)

90 (28.6)

203 (64.4)

147 (46.7)

168 (53.3)

58 (18.4)

257 (81.6)

8.9 (7.0, 11.1)

315

Class 3 (lesser
sensitization with
reversible airflow
limitation)
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Distribution of study variables by latent class assignment

238 (33.1)

114 (15.9)

305 (42.5)

47 (6.5)

68 (9.5)

447 (62.3)

137 (19.1)

134 (18.7)

294 (40.9)

337 (46.9)

234 (32.7)

261 (36.5)

221 (30.9)

77 (53, 94)

103 (14.3)

216 (30.1)

399 (55.6)

259 (36.1)

459 (63.9)

108 (15.0)

610 (85.0)

8.9 (7.4, 10.9)

718

Class 4 (multiple
sensitization with
normal lung function)

191 (49.0)

76 (19.5)

22 (56.4)

14 (3.6)

6 (1.5)

261 (66.9)

58 (14.9)

71 (18.2)
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43 (11.0)

76 (19.5)
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Class 5 (lesser
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normal lung function)
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81 (33.2)

79 (36.2)

820 (38.6)
345 (16.2)
451 (21.2)

100–500

500–1000

2 (0.8)

—
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0.5 (−0.3, 1.2)

360 (13.9)

>0

Postbronchodilator FEV1 z score

1346 (51.9)

−1.64 to 0

21 (0.8)
866 (33.4)

<−1.64

Missing

−0.2 (−1.9, −0.4)

1072 (41.3)

Prebronchodilator FEV1/FVC z
score

>0

—

−1.64 to 0

−1.0 (−1.5, −0.4)

7 (2.9)

40 (16.4)

197 (80.7)

—

−0.4 (−2.9, −1.8)

244 (100)

284 (11.0)
1216 (46.9)

<−1.64

—

−2.1 (−2.7, −1.8)

21 (0.8)

−0.2 (−1.0, 0.5)

223 (92.1)

104 (42.6)

163 (66.8)

2 (0.8)

180 (74.4)

87 (39.9)

6 (2.8)

26 (10.7)

Missing

Prebronchodilator FEV1 z score

37 (1.4)

Sensitization to other
aeroallergens

Missing

738 (28.5)
1888 (72.8)

Sensitization to dog

38 (1.5)
1263 (48.7)

Sensitization to cat

Missing

Sensitization to pets

1409 (54.3)

508 (23.9)

<100

>1000

46 (21.1)

469 (18.1)

Missing

202 (84.9)
347 (208, 556)

1546 (60.9)
210 (66, 516)

≥4%

36 (15.1)

993 (39.1)

6 (2.5)

7.0 (4.6, 10.0)

IgE (kU/L)

<4%

54 (2.1)

Blood eosinophils (%)

Missing

789 (30.4)
5.0 (2.4, 8.0)

Tobacco smoke exposure

All participants

Author Manuscript

Feature
243 (26.2)

0.1 (−0.4, 0.6)

70 (7.7)

444 (48.6)

399 (43.7)

13 (1.4)

−0.5 (−2.1, −0.8)

—

913 (100)

—

13 (1.4)

−0.7 (−1.1, −0.3)

9 (1.0)

840 (91.6)

346 (37.4)

595 (64.3)

10(1.1)

663 (72.4)

223 (29.4)

162 (21.4)

349 (46.0)

24 (3.2)

168 (18.1)

363 (182, 779)

694 (76.3)

216 (23.7)

16 (1.7)

6.0 (4.0, 9.0)

−0.3 (−0.8, 0.1)

25 (7.9)

156 (49.5)

134 (42.5)

—

−1.4 (−2.0, −0.8)

2 (0.6)

273 (86.7)

40 (12.7)

—

−0.8 (−1.3, −0.4)

1 (0.3)

79 (25.2)

7 (2.2)

17 (5.4)

1 (0.3)

21 (6.7)

—

3 (1.2)

61 (23.6)

194 (75.2)

57 (18.1)

41 (17, 70)

75 (24.3)

234 (75.7)

6 (1.9)

2.0 (1.1, 3.8)

121 (38.4)

Class 3 (lesser
sensitization with
reversible airflow
limitation)

Author Manuscript
Class 2 (multiple
sensitization with
reversible airflow
limitation)

1.3 (0.9, 1.8)

152 (21.2)

445 (62.2)

119 (16.6)

2 (0.3)

−0.8 (−1.4, −0.2)

716 (100)

—

—

2 (0.3)

0.7 (0.3, 1.2)

17 (2.4)

645 (92.0)

270 (37.6)

455 (63.4)

17 (2.4)

509 (72.6)

149 (25.9)

131 (22.8)

266 (46.3)

29 (5.0)

143 (7.9)

371 (190, 744)

513 (73.5)

185 (26.5)

20 (2.8)

5.3 (3.4, 8.1)

232 (32.3)

Class 4 (multiple
sensitization with
normal lung function)

1.1 (0.7, 1.6)

106 (27.6)

261 (68)

17 (4.4)

6 (1.5)

−0.4 (−1.0, −0.2)

354 (92.2)

30 (7.8)

—

6 (1.5)

0.6 (0.2, 1.1)

8 (2.1)

101 (26.4)

11 (2.8)

33 (8.5)

8 (2.1)

36 (9.4)

—

3 (1.0)

57 (18.1)

255 (81.0)

75 (19.2)

45 (15, 83)

62 (16.1)

322 (83.9)

6 (1.5)

2.0 (1.0, 3.0)

112 (28.7)

Class 5 (lesser
sensitization with
normal lung function)

Author Manuscript

Class 1 (multiple
sensitization with
partially reversible
airflow limitation)
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Author Manuscript
756 (29.2)

−1.64 to 0

404 (15.6)
371 (14.3)
377 (14.5)
399 (15.4)

Lowest (worst control)

Low

Higher

Highest (best control)

3 (1.2)

15 (14.6)

21 (20.4)

31 (30.1)

36 (35.0)

141 (57.8)

27 (11.2)

176 (73.0)

38 (15.8)

120 (23.8)

116 (23.0)

130 (25.8)

138 (27.4)

422 (45.6)

535 (59.2)

361 (40.0)

7 (0.8)

23 (2.4)

7 (2.2)

56 (28.7)

58 (29.7)

39 (20.0)

42 (21.5)

120 (38.1)

88 (28.6)

207 (67.2)

13 (4.2)

127 (26.7)

100 (21.1)

111 (23.4)

137 (28.8)

243 (33.8)

701 (98.9)

8 (1.1)

—

9 (1.3)

Class 4 (multiple
sensitization with
normal lung function)

81 (29.6)

82 (29.9)

60 (21.9)

51 (18.6)

116 (29.7)

376 (98.9)

4 (1.1)

—

10 (2.6)

Class 5 (lesser
sensitization with
normal lung function)

Note. By design, all variables were significantly different between latent classes, so P values are not shown. Data represent the median (25th, 95th percentile) or the number of participants (%).

1042 (40.2)

Missing

Asthma control quartile

1727 (66.6)

58 (2.2)

<−1.64

>0

52 (2.0)

Missing

All participants

Author Manuscript

Feature

Class 3 (lesser
sensitization with
reversible airflow
limitation)

Author Manuscript
Class 2 (multiple
sensitization with
reversible airflow
limitation)

Author Manuscript

Class 1 (multiple
sensitization with
partially reversible
airflow limitation)
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Author Manuscript
244

149 (61.1)
86 (35.2)
80 (32.8)

Parent with allergies

Sibling with allergies

Physician-diagnosed eczema

11 (4.5)
81 (33.2)
51 (20.9)

Non-ICS

ICS monotherapy

ICS plus additional

28 (11.5)
46 (18.9)
33 (13.5)

1

2

≥3

J Allergy Clin Immunol Pract. Author manuscript; available in PMC 2021 September 01.
13.7 (9.5, 31.5)

Exhaled nitric oxide (ppb)‡

Prebronchodilator§

476 (305, 722)

Blood eosinophils (per microliter)†

Multiple sensitization
50 (28.6, 75.0)

24 (9.9)
216 (89.3)

Monosensitization

Percentage of positive aeroallergens (of
8)

2 (0.8)

No sensitization

Sensitization*

137 (56.1)

0

Oral corticosteroid bursts, n (past year)

101 (41.4)

None

Asthma controller medications

52 (21.3)
244 (13.5)

Obesity (BMI ≥95%)

6.9 (4.9, 9.7)

Hispanic ethnicity

Asthma symptom duration (y)

N

Feature

Author Manuscript
Class 1 (multiple
sensitization with
partially reversible
airflow limitation)

15.9 (9.0, 27.7)

425 (260, 637)

42.9 (28.6, 71.4)

783 (85.4)

120 (13.1)

14 (1.5)

108 (11.7)

126 (13.6)

136 (14.7)

556 (60.0)

171 (18.5)

359 (38.8)

29 (3.1)

367 (39.6)

366 (39.5)

396 (42.8)

571 (61.7)

926 (17.7)

155 (16.7)

6.7 (4.5, 9.2)

926

Class 2 (multiple
sensitization with
reversible airflow
limitation)

9.3 (6.4, 12.9)

151 (89, 248)

0 (0, 12.5)

39 (12.4)

69 (22.0)

206 (65.6)

40 (12.7)

24 (7.6)

54 (17.1)

197 (62.5)

69 (21.9)

111 (35.2)

18 (5.7)

117 (37.1)

90 (28.6)

135 (42.9)

181 (57.5)

315 (23.8)

38 (12.1)

6.4 (4.6, 8.5)

315

Class 3 (lesser
sensitization with
reversible airflow
limitation)

Author Manuscript

Other features of the participants

13.0 (7.0, 22.5)

426 (230, 594)

618 (88.2)42.9 (25.0,
62.5)

71 (10.1)

12 (1.7)

78 (10.9)

106 (14.8)

159 (22.1)

375 (52.2)

156 (21.7)

324 (45.1)

31 (4.3)

207 (28.8)

323 (45.0)

322 (44.8)

446 (62.1)

718 (23.4)

81 (11.3)

6.2 (4.1, 8.1)

718

Class 4 (multiple
sensitization with
normal lung function)

7.4 (5.8, 11.0)

146 (82, 229)

0 (0, 12.5)

71 (18.6)

70 (18.3)

241 (63.1)

38 (9.7)

45 (11.5)

76 (19.5)

231 (59.2)

91 (23.3)

166 (42.6)

19 (4.9)

114 (29.2)

139 (35.6)

160 (41.0)

235 (60.3)

390 (24.9)

39 (10.0)

6.1 (4.1, 7.8)

390

Class 5 (lesser
sensitization with normal
lung function)

Author Manuscript

TABLE II.

<.001

<.001

<.001

<.001

<.001

<.001

.123

.681

<.001

<.001

<.001

P value
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Author Manuscript

Author Manuscript
74 (67, 77)
80 (74, 86)

FEV1 (% predicted)

FEV1/FVC (% predicted)

0.5 (0.2, 1.0)

0.8 (0.4, 2.3)

96 (92, 101)

102 (96, 107)

105 (98, 113)

89 (83, 95)

92 (87, 96)

103 (96, 109)

Class 1, n = 205; class 2, n = 821; class 3, n = 258; class 4, n = 636; class 5, n = 322.

#

Class 1, n = 241; class 2, n = 903; class 3, n = 308; class 4, n = 709; class 5, n = 380.

Class 1, n = 219; class 2, n = 751; class 3, n = 255; class 4, n = 584; class 5, n = 309.

¶

∥

Class 1, n = 244; class 2, n = 913; class 3, n = 315; class 4, n = 716; class 5, n = 384.

§

Class 1, n = 55; class 2, n = 391; class 3, n = 144; class 4, n = 370; class 5, n = 224.

‡

Class 1, n = 236; class 2, n = 910; class 3, n = 309; class 4, n = 698; class 5, n = 385.

Class 1, n = 242; class 2, n = 917; class 3, n = 314; class 4, n = 701; class 5, n = 382.

†

*

Note. Data represent the median (25th, 95th percentile) or the number of participants (%).

Methacholine PC20#

91 (86, 96)

88 (92, 95)

FEV1 (% predicted)¶

FEV1/FVC (% predicted)∥

97 (88, 105)

FVC (% predicted)∥

Postbronchodilator

89 (83, 96)

FVC (% predicted)

Feature

1.6 (0.6, 3.0)

96 (90, 100)

96 (90, 102)

100 (93, 107)

90 (84, 95)

90 (84, 95)

99 (93, 105)

Class 3 (lesser
sensitization with
reversible airflow
limitation)

Author Manuscript
Class 2 (multiple
sensitization with
reversible airflow
limitation)

1.4 (0.6, 3.9)

100 (96, 103)

116 (111, 123)

117 (110, 123)

94 (90, 99)

108 (104, 114)

116 (109, 123)

Class 4 (multiple
sensitization with
normal lung function)

2.8 (1.2, 6.3)

101 (97, 104)

113 (108, 119)

113 (106, 119)

97 (93, 100)

107 (103, 114)

111 (105, 118)

Class 5 (lesser
sensitization with normal
lung function)

Author Manuscript

Class 1 (multiple
sensitization with
partially reversible
airflow limitation)

<.001

<.001

<.001

<.001

<.001

<.001

<.001

P value
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Author Manuscript

Author Manuscript

z score <LLN
7 (1.1)

52 (27.4)

−1.0 (−1.7, −0.2)
85 (13.3)

−0.6 (−1.3, 0.1)

96 (91, 100)

10 (5.2)
93 (87, 99)

LLN equivalent to a z score of ≤1.64.

*

Note. Data represent the median (25th, 95th percentile) or the number of participants (%).

z score <LLN

z score

FEV1/FVC (% predicted)

1.1 (0.5, 1.7)

113 (106, 121)

118 (109, 127)

0.6 (−0.3, 1.3)

107 (96, 116)

z score

115 (107, 125)

321 (40.0)

126 (59.7)

FEV1 (% predicted)

−1.4 (−2.1, −0.8)

90 (83, 95)

36 (4.5)

0.3 (−0.3, 1.0)

104 (96, 112)

116 (107, 124)

803, 639

Class 2 (multiple
sensitization with
reversible airflow
limitation)

−1.9 (−2.5, −1.0)

85 (78, 92)

37 (17.5)

FVC (% predicted)

Postbronchodilator

z score <LLN

z score

FEV1/FVC (% predicted)

z score <LLN*

−0.4 (−1.3, 0.5)

94 (84, 107)

z score

111 (102, 121)

FEV1 (% predicted)

211, 190

FVC (% predicted)

Prebronchodilator

N (pre-, postbronchodilator)

Feature

Class 1 (multiple
sensitization with partially
reversible airflow
limitation)

30 (14.6)

−0.6 (−1.2, −0.1)

96 (91, 99)

2 (1.0)

0.7 (0.1, 1.5)

109 (102, 118)

115 (107, 123)

101 (39.1)

−1.3 (−1.9, −0.6)

90 (85, 96)

8 (3.1)

0.2 (−0.4, 0.8)

102 (94, 110)

115 (106, 122)

258, 206

Class 3 (lesser sensitization
with reversible airflow
limitation)

29 (6.4)

−0.2 (−0.8, 0.4)

99 (94, 102)

3 (0.7)

2.1 (1.5, 2.8)

126 (118, 135)

128 (119, 137)

143 (23.0)

−0.9 (−1.6, −0.3)

94 (88, 98)

8 (1.3)

1.6 (0.9, 2.2)

119 (111, 127)

127 (119, 137)

622, 456

Class 4 (multiple
sensitization with normal
lung function)

Author Manuscript

Lung function values in the 5 latent classes at the end of follow-up

7 (3.0)

−0.1 (−0.6, 0.5)

99 (96, 103)

—

2.0 (1.4, 2.7)

124 (116, 133)

125 (117, 133)

35 (11.0)

−0.7 (−1.2, −0.1)

96 (92, 100)

—

1.6 (1.0, 2.2)

119 (112, 127)

124 (116, 134)

318, 234

Class 5 (lesser
sensitization with normal
lung function)

Author Manuscript

TABLE III.

<.001

<.001

<.001

<.001

<.001

<.001

<.001

<.001

<.001

<.001

<.001

<.001

<.001

<.001

P value
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